Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped down before the market opened on Friday following insider selling activity. The stock had previously closed at $43.96, but opened at $42.91. Hims & Hers Health shares last traded at $44.71, with a volume of 4,937,687 shares.

Specifically, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $45.06, for a total transaction of $5,773,402.62. Following the transaction, the chief executive officer directly owned 89,521 shares in the company, valued at approximately $4,033,816.26. This represents a 58.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Ratings Changes

HIMS has been the topic of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research report on Monday, June 23rd. Bank of America increased their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research report on Tuesday, April 29th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Piper Sandler reiterated a “neutral” rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Price Performance

The company has a market capitalization of $10.06 billion, a PE ratio of 55.66, a PEG ratio of 2.97 and a beta of 2.08. The firm has a fifty day moving average of $51.71 and a two-hundred day moving average of $45.78. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company’s revenue was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtus Advisers LLC purchased a new stake in Hims & Hers Health in the 2nd quarter worth approximately $26,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health in the 2nd quarter worth approximately $29,000. Bessemer Group Inc. lifted its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the 1st quarter worth approximately $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after buying an additional 600 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.